These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 25446664)
41. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539 [TBL] [Abstract][Full Text] [Related]
42. The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer. Zhao H; Li R; Wang X; Lu X; Hu M; Zhang J; Zhao X; Song X; Liu Y J Ovarian Res; 2020 Sep; 13(1):113. PubMed ID: 32958014 [TBL] [Abstract][Full Text] [Related]
43. Targeting SRC and tubulin in mucinous ovarian carcinoma. Liu T; Hu W; Dalton HJ; Choi HJ; Huang J; Kang Y; Pradeep S; Miyake T; Song JH; Wen Y; Lu C; Pecot CV; Bottsford-Miller J; Zand B; Jennings NB; Ivan C; Gallick GE; Baggerly KA; Hangauer DG; Coleman RL; Frumovitz M; Sood AK Clin Cancer Res; 2013 Dec; 19(23):6532-43. PubMed ID: 24100628 [TBL] [Abstract][Full Text] [Related]
44. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059 [TBL] [Abstract][Full Text] [Related]
45. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Carrara L; Guzzo F; Roque DM; Bellone S; Emiliano C; Sartori E; Pecorelli S; Schwartz PE; Rutherford TJ; Santin AD Gynecol Oncol; 2012 Apr; 125(1):231-6. PubMed ID: 22209775 [TBL] [Abstract][Full Text] [Related]
46. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Rattan R; Graham RP; Maguire JL; Giri S; Shridhar V Neoplasia; 2011 May; 13(5):483-91. PubMed ID: 21532889 [TBL] [Abstract][Full Text] [Related]
47. [Metformin inhibits the proliferation of hypopharyngeal carcinoma Fadu cells and enhances the chemotherapeutic sensitivity of cells]. Zhang M; Li X; Lu X Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Apr; 49(4):317-22. PubMed ID: 24931021 [TBL] [Abstract][Full Text] [Related]
48. Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer. Yuan J; Kang JL; Liao H; Wang XX; Nie ML; Shuai R; Deng C Anticancer Agents Med Chem; 2015; 15(10):1308-16. PubMed ID: 26118713 [TBL] [Abstract][Full Text] [Related]
49. Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. Tan XL; Bhattacharyya KK; Dutta SK; Bamlet WR; Rabe KG; Wang E; Smyrk TC; Oberg AL; Petersen GM; Mukhopadhyay D Pancreas; 2015 May; 44(4):636-47. PubMed ID: 25875801 [TBL] [Abstract][Full Text] [Related]
51. Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells. Huang KC; Yang J; Ng MC; Ng SK; Welch WR; Muto MG; Berkowitz RS; Ng SW Eur J Cancer; 2016 Nov; 67():152-163. PubMed ID: 27669502 [TBL] [Abstract][Full Text] [Related]
52. Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo. Hashimoto K; Morishige K; Sawada K; Ogata S; Tahara M; Shimizu S; Sakata M; Tasaka K; Kimura T Biochem Biophys Res Commun; 2007 Apr; 356(1):72-7. PubMed ID: 17343825 [TBL] [Abstract][Full Text] [Related]
53. Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. Tang G; Guo J; Zhu Y; Huang Z; Liu T; Cai J; Yu L; Wang Z Int J Oncol; 2018 Jun; 52(6):1899-1911. PubMed ID: 29620187 [TBL] [Abstract][Full Text] [Related]
54. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gotlieb WH; Saumet J; Beauchamp MC; Gu J; Lau S; Pollak MN; Bruchim I Gynecol Oncol; 2008 Aug; 110(2):246-50. PubMed ID: 18495226 [TBL] [Abstract][Full Text] [Related]
55. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice. Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187 [TBL] [Abstract][Full Text] [Related]
56. Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells. Li B; Li X; Ni Z; Zhang Y; Zeng Y; Yan X; Huang Y; He J; Lyu X; Wu Y; Wang Y; Zheng Y; He F Oncotarget; 2016 Sep; 7(37):59458-59470. PubMed ID: 27449090 [TBL] [Abstract][Full Text] [Related]
57. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer. Park S; Willingham MC; Qi J; Cheng SY Endocr Relat Cancer; 2018 Oct; 25(10):865-877. PubMed ID: 29914872 [TBL] [Abstract][Full Text] [Related]
58. Assessing the antitumor effects of metformin on ovarian clear cell carcinoma. Takemori S; Morisada T; Osaka M; Watanabe M; Tajima A; Tanigaki S; Kobayashi Y Hum Cell; 2024 Sep; 37(5):1462-1474. PubMed ID: 39115639 [TBL] [Abstract][Full Text] [Related]
59. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Pashaei-Asl F; Pashaei-Asl R; Khodadadi K; Akbarzadeh A; Ebrahimie E; Pashaiasl M Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1483-1487. PubMed ID: 28884602 [TBL] [Abstract][Full Text] [Related]
60. SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells. Wu Y; Gao WN; Xue YN; Zhang LC; Zhang JJ; Lu SY; Yan XY; Yu HM; Su J; Sun LK Exp Cell Res; 2018 Jun; 367(2):137-149. PubMed ID: 29580688 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]